S&P 500 Edges Higher; Nordstrom Shares Plummet
U.S. stocks traded slightly higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Wednesday.
Why SciSparc Stock Is Skyrocketing Today
SciSparc Ltd (NASDAQ: SPRC) shares are soaring Wednesday after the company announced additional pre-clinical results of its psychedelic-based pharma collaboration for treatment of cocaine addiction using MEAI.
SciSparc Announces Additional Pre-Clinical Results Of Psychedelic-Based Treatment For Cocaine Addiction Using MEAI
Results indicate significant decrease in cocaine craving in a sub-group that received the treatment
TEL AVIV, Israel, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage
SciSparc Enters Into Agreement To Acquire American Food Supplements And Cosmetics Brand For $1M
TEL AVIV, Israel, Aug. 18, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to
Why Hill International Shares Are Trading Higher By 58%: Here Are 25 Stocks Moving Premarket
Gainers
Hill International, Inc. (NYSE: HIL) shares rose 58.1% to $2.75 in pre-market trading after the company agreed to be acquired by Global Infrastructure Solutions Inc. for $2.85 per share.
This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday
Gainers
Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 115.7% to close at $17.73 on volatility following the company's IPO earlier this month.
Scisparc Signs Clinical Trial Agreement With Yale University To Conduct Its Phase IIB Trial In Tourette Syndrome
SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system,
SciSparc Closer To Phase II-B Trial Of Its Dronabinol Based Drug For The Treatment Of Tourette Syndrome
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has started the process of preparing for an Investigational New Drug Application (“IND”) with the U.S.